On the other hand, although our results exclude major transcriptional modifications of p16INK4a in primary tumours, we cannot rule out the possibility of translational or post-translational changes that could explain the high proportion of NB with lack of p16INK4a immunostaining in the series reported by Takita et al (1998). The gene discussed is CDKN2A; the disease is neoplasm.